Endonovo Therapeutics, Inc.

Equities

ENDV

US29272H3003

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 01:37:45 2024-04-25 pm EDT			5-day change	1st Jan Change
0.0024 ^USD	-4.00%		-14.29%	-72.41%

2023	Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval	CI

Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

November 21, 2022 at 04:32 pm EST

Endonovo Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 0.01096 million compared to USD 0.00779 million a year ago. Net loss was USD 0.60336 million compared to USD 1.52 million a year ago.
For the nine months, sales was USD 0.013892 million compared to USD 0.072789 million a year ago. Net loss was USD 5.54 million compared to USD 5.5 million a year ago. Basic loss per share from continuing operations was USD 0.05 compared to USD 0.1 a year ago.

Latest news about Endonovo Therapeutics, Inc.

Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Dec. 29	CI
Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval	23-10-12	CI
Endonovo Therapeutics, Inc.'s SofPulse Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution	23-08-22	CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
Endonovo Therapeutics, Inc. Announces Pending Agreement to Develop Telehealth Division	23-06-07	CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI
Endonovo Therapeutics, Inc. Launches SofPulse into the Veterans Administration	23-05-02	CI
Endonovo Therapeutics, Inc. Announces Moving Forward in Its Clinical Development in the Field of Traumatic Brain Injury Treatment	23-04-25	CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17	CI
Endonovo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	23-04-16	CI
Endonovo Therapeutics, Inc. Announces Final Stages to Receive Taiwan FDA License to Distribute in Taiwan	23-03-23	CI
Endonovo Announces Distribution Agreement with Academy Medical	23-03-06	CI
Endonovo Partners with International Distributor for SofPulse Line	23-01-26	CI
Endonovo Therapeutics Details Plan to Spin Off Medical Device Division as A Listed Public Company	23-01-09	CI
Endonovo Therapeutics, Inc. agreed to Spin-Off Medical Device Division of Endonovo Therapeutics.	23-01-08	CI
Endonovo Therapeutics, Inc. Appoints Ira Weisberg President to Guide Global Medical Expansion	22-11-30	CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-21	CI
Endonovo Therapeutics, Inc. entered into an Asset Purchase Agreement to acquire Substantially all of the assets and assume certain liabilities of Western Star.	22-09-26	CI
Endonovo Therapeutics Releases Comparative Analysis Demonstrating	22-07-28	CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-19	CI
Endonovo Therapeutics Signs Agreement with NAMSA to Develop Reimbursement Strategy for Endonovo Medical Products	22-04-25	CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-14	CI
Endonovo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	22-04-13	CI
Endonovo Therapeutics Inc. Appoints Garry Michael Kann as Head of Corporate Development	22-03-01	CI
Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-19	CI

Chart Endonovo Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.

Sector

Biotechnology & Medical Research

Calendar

2024-06-16 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ENDONOVO THERAPEUTICS, INC.	-72.41%	873K
VERTEX PHARMACEUTICALS INCORPORATED	-1.95%	104B
REGENERON PHARMACEUTICALS, INC.	+1.98%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.71%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-16.10%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+3.93%	13.98B
SAREPTA THERAPEUTICS, INC.	+31.99%	11.66B

Bio Therapeutic Drugs